The Effects of Exogenous Beta-Hydroxybutyrate Supplementation on Metrics of Safety and Health

Matthew Stefan*, Matthew Sharp, Raad Gheith, Ryan Lowery, Jacob Wilson

Research Department, The Applied Science and Performance Institute, Tampa, Florida, USA

Email address: mstefan@theaspi.com (M. Stefan), msharp@theaspi.com (M. Sharp), rgeith@theaspi.com (R. Gheith), rlowery@theaspi.com (R. Lowery), jwilson@theaspi.com (J. Wilson)

*Corresponding author

To cite this article:
Matthew Stefan, Matthew Sharp, Raad Gheith, Ryan Lowery, Jacob Wilson. The Effects of Exogenous Beta-Hydroxybutyrate Supplementation on Metrics of Safety and Health. International Journal of Nutrition and Food Sciences. Vol. 9, No. 6, 2020, pp. 154-162.
doi: 10.11648/j.ijnfs.20200906.13

Received: November 9, 2020; Accepted: November 24, 2020; Published: December 8, 2020

Abstract: The ketogenic diet is a high-fat, very low-carbohydrate, moderate-protein diet that will induce a state of ketosis. Ketosis is a metabolic state characterized by elevated ketone body production in response to the absence of carbohydrates. Some drawbacks of the ketogenic diet are that it can be difficult to adhere to due to its restrictive nature, and it can also cause some undesirable side effects like gastrointestinal distress and increases in apoB-lipoproteins. In order to maximize the benefit of ketosis and to minimize side effects, supplementing with exogenous beta-hydroxybutyrate may induce a state of temporary ketosis without undesirable side effects. In the present study, 22 healthy male and female adults consumed 12.75 grams of beta-hydroxybutyrate salts or maltodextrin placebo twice daily for 90 days. Comprehensive blood safety analysis, body composition, bone densitometry, psychological and immune surveys, and blood pressure were administered at baseline, 30, 60, and 90 days. There were no significant differences in any measures collected, indicating that exogenous beta-hydroxybutyrate had no detrimental impact on fasting blood values such as electrolyte levels, glucose, hemoglobin A1c, complete blood count, body composition, bone density, psychological well-being, immune status, or blood pressure. We conclude that supplementing with exogenous beta-hydroxybutyrate is safe and well-tolerated by healthy adults.

Keywords: Beta-Hydroxybutyrate, Ketosis, Safety, Exogenous Ketones

1. Introduction

The ketogenic diet is categorized as a high-fat, very-low carbohydrate, and moderate protein dietary strategy that is meant to mimic a fasted state by restricting carbohydrate intake. Research has commonly defined the intakes of a ketogenic diet as less than 50 grams of carbohydrates per day, or 5 to 10 percent of total caloric contribution coming from carbohydrates, with fat contributing up to 90 percent of total caloric intake [1, 2]. The goal of the ketogenic diet is to induce ketosis – a metabolic state characterized by increased ketone body production in response to the absence of carbohydrates. In order to reach a state of nutritional ketosis, blood ketone concentration should be between 0.5 millimolar (mM) and 3.0 mM [3]. This rise in endogenous ketones is dependent on macronutrient availability of glucose and fatty acids, and the hormonal signaling of glucagon, insulin, and cortisol.

There are many benefits to human health for being in a state of ketosis from consuming a ketogenic diet. Weight loss occurs due to the reliance on fatty acid storage, and from the mitochondria regaining their metabolic flexibility (countering insulin resistance) [4, 5]. Young et al. demonstrated that as ketone levels rose, fat loss rose as well [6]. In addition to weight loss, research has shown that the ketogenic diet does not have a negative impact on hunger hormones despite a decline in total caloric intake [7]. To achieve an appetite suppressive effect, ketones concentrations only need to reach mild ketosis (greater than 0.5 mM) [8, 10]. Research has also demonstrated that the application of the ketogenic diet can have therapeutic benefits on diseases that impact metabolism [9]; reduce the incidence of seizures in children with epilepsy [11], improve outcomes of certain neurogenerative diseases like Parkinson’s Disease [12], may help control glycolytic phenotype of various cancers by limiting glucose availability.
[13], and lower glucose and hemoglobin A1c concentrations in individuals with type 2 diabetes [14, 15]. Lastly, elevated blood ketones could improve endurance performance and further optimize substrate metabolism by providing an alternative source for oxidative phosphorylation [16, 17].

In addition to being carbohydrate restrictive, adherence to the ketogenic diet can be difficult due to some undesirable side effects like gastrointestinal discomfort [18] and increases in apoB-lipoproteins [19]. Therefore, temporary and rapid rises in blood ketone concentrations with no dietary changes may be of potential interest and benefit [20]; hence, the relevance of exogenous ketones [21-23]. The safety of ketone esters has been previously explored, however, there is a void in the literature on the safety of ketone salts, which is what this study investigated. One previous study on the safety of ketone salts demonstrated that two servings of 7 grams of beta-hydroxybutyrate (BHB) combined with erythritol, L-Taurine, and L-Leucine was safe as demonstrated by no changes in complete blood count (CBC) or biomarkers of a comprehensive metabolic panel over 6 weeks [24]. Moreover, markers of cardiovascular health, such as blood pressure, improved while heart rate remained unchanged. The purpose of this study is to extend this research to 90 days with a dosage of 12.75 grams twice per day with additional metrics of safety and health.

2. Methods

2.1. Subject Criteria

Twenty-two healthy male and female subjects aged 18 to 50 years old enrolled for study participation. Exclusion criteria included: hypertension, obesity (body mass index [BMI] >30 kg/m²), smoking or using smokeless tobacco, taking any prescription medication, or having any underlying health conditions (metabolic, heart disease, diabetes, kidney disease). This study was approved by an external institutional review board (Integ Review IRB, Austin, TX, USA) and all procedures were in agreement with institutional guidelines and the Declaration of Helsinki. Prior to engagement in any study procedures, subjects provided written informed content.

Table 1. Descriptive Subject Characteristics.

|            | BHB   | PLA   |
|------------|-------|-------|
| Sample Size| (n=11) | (n=11) |
| Age (years)| 44.45 ± 7.30 | 45.55 ± 9.05 |
| Height (cm)| 166.49 ± 9.80 | 169.03 ± 11.15 |
| Weight (kg) | 72.79 ± 14.67 | 78.81 ± 18.07 |
| Body Mass Index (kg/m²) | 26.32 ± 5.13 | 27.27 ± 3.66 |

2.2. Study Design

The study design was a randomized, double-blinded, placebo-controlled trial. Subjects were stratified into quartiles based on BMI and subjects from each quartile were randomly assigned to conditions using a random number generator (random.org). The conditions were sent to the primary investigator in white packages labeled “A” or “B”. These were administered as 12.75-gram servings of a R-Beta Hydroxybutyrate (BHB) salt blend (KetoNAT™; Science Backed Solutions, LLC; Melissa, TX, USA) or a similarly flavored iso-energetic, iso-volumetric maltodextrin placebo twice daily for 90 days for a total of 25.5-grams of the respective condition, daily. Subjects underwent baseline testing (PRE) which included: blood draw for safety measures (complete blood count, comprehensive metabolic panel, automated differential, and hemoglobin A1c), resting blood pressure and heart rate, psychological mood assessment (Profile of Mood States; [POMS]), immune status questionnaire, body composition and bone densitometry. Following PRE testing, subjects were given a 30-day supply of either condition “A” or condition “B”. Subjects were instructed to consume one serving in the morning and one serving in the afternoon with at least three hours of separation between servings. Subjects were also asked to track their caloric intake 3 days every week for the duration of the study. Lastly, subjects submitted VAS (visual analog scales) to report subjective measures of satiety, hunger, and psychological feelings (well-being, mental clarity, etc.). Testing was repeated for all study procedures in an identical manner to PRE at 30 days, 60 days, and 90 days following the original PRE testing date, with the exception of the DXA which was only performed at PRE and 90 days. Study procedures are further described below.

2.3. Bone Densitometry and Body-Composition Analysis

Bone densitometry and body composition was determined by a whole-body scan on a dual-energy x-ray absorptiometry device (Horizon A DXA System, Hologic Inc, Marlborough, MA, USA). Fat-free mass, fat mass, body fat percentage, bone mineral content, and bone density was determined for the total body with the subject lying in a supine position with knees and elbows extended. Subjects were instructed not to move for the entire duration of the scan (approximately 5 minutes). Results from each scan were uploaded and accessed on computer that was directly linked to the DXA device. Calibration of the DXA device was done against a phantom provided by the manufacturing company prior to testing.

2.4. Venous Blood Measures

Venous blood was extracted by venipuncture of the antecubital vein using a 21-gauge syringe and collected into a 10mL EDTA vacutainer tube (BD Vacutainer®, Becton, Dickinson and Company, Franklin Lakes, NJ, USA) by a certified phlebotomist. Afterward, blood samples were centrifuged at 2500 rpm for 10 minutes at 4°C. Resulting serum samples were then aliquoted and stored at −80°C until further analysis. Samples were thawed once and analyzed in duplicate in the same assay for each analysis to avoid compounded inter-assay variance.

2.5. Blood Pressure and Heart Rate

Subjects rested in a supine position for 5 min in a quiet room at 228°C before the baseline hemodynamic measurements were obtained. Resting brachial blood pressure and heart rate were measured on the right arm with an automated digital...
oscillometric sphygmomanometer (Omron, Model HEM 705-CP; Omron Corporation, Shimogyo-ku, Kyoto, Japan). Three readings separated by 1-min intervals were taken, and the mean was used for the analysis.

2.6. Immune Status Questionnaire (ISQ) and Profile of Mood States (POMS)

The Immune Status Questionnaire (ISQ) is a validated self-assessment of subjective values of seven different common symptoms associated with disease [25]. The ISQ was scored on a 5-point Likert scale from 0 to 4 for how often the subject has had the following symptoms in the past week: Never, Sometimes, Regularly, Often, and Almost Always. The values were summed up to equal a raw score. The raw score was then converted into a final score between zero and ten, with 0 being the poor immune status, and ten being excellent immune status [26].

The Profile of Mood States is a validated self-assessment of subjective values of forty different moods [25]. Those moods then fall into seven categories: Tension, Anger, Fatigue, Depression, Esteem-Related, Vigor, and Confusion. Subjects were asked to assess each of the forty moods, and if they are feeling that particular mood “right now”. Subjects assessed the moods according to a 5-point Likert scale from 0 to 4: Not at All, A Little, Moderately, Quite a Lot, Extremely. The following formula was used to determine the overall POMS score:

\[
(Tension + Depression + Anger + Fatigue + Confusion) - (Vigor + Esteem-Related) + 100
\]

A lower score indicated a better mood, while a higher score indicated a poor mood [24].

2.7. Visual Analog Scales for Perceived Hunger and Perceived Mental Clarity

The perceptual measures collected for the study were perceived Hunger and perceived Mental Clarity. Hunger and Mental Clarity scales consisted of a scalar representation numbering from 0-10. On the Hunger Scale, visual descriptors of “not hungry”, “adequately hungry” and “very hungry” presented at numbers 0, 5, and 10, respectively. On the Mental Clarity scale, visual descriptors of “Poor Mental Clarity”, “Adequate Mental Clarity”, and “Very Mentally Clear” are presented at numbers 0, 5, and 10, respectively.

2.8. Calorie and Macronutrient Reporting

Subjects were asked to record, and then report, their caloric intake three times per week using a mobile tracking application (MyFitnessPal, San Francisco, CA, USA).

2.9. Statistical Analysis

All statistical analyses were performed at the completion of the study using GraphPad Prism (Version 8, San Diego, CA, USA). Dependent variables were assessed for normality (Shapiro-Wilk test) and homogeneity of variances (Levene’s test). Two-way mixed model analysis of variance (ANOVA) was performed assuming group and time as fixed factors and subjects as a random factor. Whenever a significant F value was obtained, a post hoc test with a Bonferroni adjustment was used to for multiple comparisons purposes. The alpha level was set at \( p \leq 0.05 \). Data are reported as mean ± standard deviation.

3. Results

3.1. Complete Blood Count

There was no significant between or within group differences in Complete Blood Count values (\( p > 0.05 \), Table 2). Mean and standard deviation are displayed in Table 2.

| Table 2. Complete Blood Count Results. |
|----------------------------------------|
| PRE | 30 DAY | 60 DAY | 90 DAYS | p Value |
|---------|--------|--------|--------|---------|
| WBC (K/uL) | | | | |
| BHB | 5.13 ± 0.96 | 5.07 ± 0.95 | 5.38 ± 1.07 | 6.62 ± 2.49 | 0.1001 |
| PLA | 5.91 ± 1.03 | 5.91 ± 1.05 | 5.94 ± 1.03 | 6.19 ± 1.06 | 0.1084 |
| RBC (M/uL) | | | | |
| BHB | 4.66 ± 0.41 | 4.61 ± 0.33 | 4.67 ± 0.34 | 4.70 ± 0.39 | 0.1203 |
| PLA | 4.36 ± 0.25 | 4.44 ± 0.34 | 4.37 ± 0.38 | 4.31 ± 0.40 | 0.1233 |
| Hemoglobin (g/dL) | | | | |
| BHB | 14.43 ± 1.06 | 14.28 ± 0.85 | 14.37 ± 0.89 | 14.45 ± 1.01 | 0.1233 |
| PLA | 13.40 ± 1.25 | 13.64 ± 1.22 | 13.31 ± 1.29 | 13.15 ± 1.46 | 0.1246 |
| Hematocrit (%) | | | | |
| BHB | 47.64 ± 3.07 | 46.82 ± 2.47 | 47.17 ± 2.76 | 46.92 ± 3.24 | 0.1246 |
| PLA | 44.44 ± 3.05 | 45.05 ± 3.23 | 45.05 ± 3.23 | 44.05 ± 3.45 | 0.1246 |
| MCV (fl) | | | | |
| BHB | 102.36 ± 3.41 | 101.55 ± 3.53 | 101.00 ± 3.66 | 100.00 ± 3.29 | 0.8246 |
| PLA | 101.91 ± 6.69 | 101.64 ± 6.09 | 101.09 ± 6.27 | 100 ± 7.17 | 0.9716 |
| MCHC (pg) | | | | |
| BHB | 31.01 ± 1.01 | 31.00 ± 1.39 | 30.85 ± 1.11 | 30.85 ± 1.07 | 0.9812 |
| PLA | 30.73 ± 2.60 | 30.85 ± 2.76 | 30.60 ± 2.53 | 30.59 ± 2.81 | 0.9812 |
| MCHC (g/dL) | | | | |
| BHB | 30.29 ± 0.46 | 30.50 ± 0.66 | 30.52 ± 0.79 | 30.85 ± 0.71 | 0.9812 |
| PLA | 30.10 ± 0.95 | 30.26 ± 1.08 | 30.24 ± 0.90 | 30.55 ± 1.06 | 0.9812 |
|                  | PRE       | 30 DAY    | 60 DAY    | 90 DAYS   | p Value |
|------------------|-----------|-----------|-----------|-----------|---------|
| BHB (UL/L)       | 13.15 ± 0.59 | 13.14 ± 0.57 | 12.94 ± 0.43 | 12.96 ± 0.47 | 0.4562  |
| PLA (UL/L)       | 12.73 ± 3.26  | 13.30 ± 1.06  | 13.30 ± 1.04  | 13.50 ± 0.42  |         |
| Platelets (k/µL)| 218.64±5.86  | 230.73±70.03  | 232.27±65.23  | 236.73±79.15  | 0.4181  |
| BHB (UL/L)       | 12.73 ± 3.26  | 13.30 ± 1.06  | 13.30 ± 1.04  | 13.50 ± 0.42  |         |
| PLA (UL/L)       | 218.09±34.31  | 217.5±33.87   | 217.64±40.66  | 222.00±45.73  |         |

Data reported in mean and standard deviation. P-value is from group by time interaction effect.

### 3.2. Automated Differential

There was no significant between or within group differences in any values of Automated Differential Cell Count (p > 0.05, Table 3). Mean and standard deviation are displayed in Table 3.

**Table 3. Automated Differential Cell Count**

|                  | PRE       | 30 DAY    | 60 DAY    | 90 DAYS   | p Value |
|------------------|-----------|-----------|-----------|-----------|---------|
| Lymphocytes (%)  | 35.77 ± 8.38 | 35.34 ± 7.83 | 35.68 ± 8.83 | 30.99 ± 10.14 | 0.2397  |
| BHB (k/µL)       | 218.64±5.86  | 230.73±70.03  | 232.27±65.23  | 236.73±79.15  | 0.4181  |
| PLA (k/µL)       | 218.09±34.31  | 217.5±33.87   | 217.64±40.66  | 222.00±45.73  |         |

Data reported in mean and standard deviation. P-value is from group by time interaction effect.

### 3.3. Comprehensive Metabolic Panel

There was no significant between or within group differences in any values of the comprehensive metabolic panel (p > 0.05, Table 4). Mean and standard deviation are displayed in Table 4.

**Table 4. Comprehensive Metabolic Panel**

|                  | PRE       | 30 DAY    | 60 DAY    | 90 DAY    | p Value |
|------------------|-----------|-----------|-----------|-----------|---------|
| Total Protein (g/dL) | 6.65 ± 0.35 | 6.48 ± 0.28 | 6.51 ± 0.38 | 6.48 ± 0.43 | 0.5227  |
| PLA (g/dL)       | 6.58 ± 0.41  | 6.56 ± 0.44  | 6.47 ± 0.36  | 6.42 ± 0.38  |         |
| Albumin (g/dL)   | 4.49 ± 0.22  | 4.28 ± 0.22  | 4.28 ± 0.22  | 4.44 ± 0.28  | 0.4284  |
| Metric                          | PLA          | PRE          | 30 DAY       | 60 DAY       | 90 DAY       | p Value |
|--------------------------------|--------------|--------------|--------------|--------------|--------------|---------|
| Globulin (g/dL)                | 4.40 ± 0.20  | 4.29 ± 0.25  | 4.2 ± 0.20   | 4.29 ± 0.29  |              |         |
| Blood Urea Nitrogen (BUN) (mg/dL) | 52.73 ± 11.42 | 50.09 ± 13.48 | 49.91 ± 13.23 | 50.09 ± 11.69 |              | 0.4123  |
| ALB: GLOB (U/L)                | 52.64 ± 14.70 | 51.82 ± 15.09 | 52.45 ± 12.23 | 54.09 ± 12.93 |              |         |
| Bilirubin (mg/dL)              | 2.15 ± 0.05  | 2.2 ± 0.18   | 2.25 ± 0.26  | 2.05 ± 0.42  |              | 0.8957  |
| ALP                            | 2.10 ± 0.24  | 1.97 ± 0.17  | 1.97 ± 0.17  | 1.91 ± 0.23  |              | 0.4320  |
| Alkaline Phosphate (U/L)       | 2.05 ± 0.23  | 1.89 ± 0.16  | 1.88 ± 0.17  | 2.05 ± 0.30  |              |         |
| AST (U/L)                      | 0.66 ± 0.21  | 0.63 ± 0.11  | 0.65 ± 0.22  | 0.62 ± 0.17  |              | 0.8334  |
| Acid Phosphatase (mg/l)        | 0.57 ± 0.21  | 0.55 ± 0.14  | 0.63 ± 0.21  | 0.54 ± 0.17  |              |         |
| BUN (mg/dL)                    |              |              |              |              |              |         |
| Creatinine (mg/dL)             | 0.86 ± 0.22  | 0.90 ± 0.23  | 0.92 ± 0.22  | 0.89 ± 0.23  |              | 0.3388  |
| Potassium (mg/dL)              | 0.85 ± 0.13  | 0.91 ± 0.13  | 0.89 ± 0.16  | 1.58 ± 2.17  |              |         |
| Blood Urea Nitrogen (BUN) (mg/dL) | 24.23 ± 4.84  | 21.30 ± 0.14  | 21.40 ± NA   | 21.40 ± NA/A |              | 0.0881  |
| eGFR (mL/min)                  | 22.48 ± 0.86  | 24.73 ± 2.11  | 25.23 ± 1.27  | 23.30 ± NA/A  |              |         |
| Sodium (mg/dL)                 | 88.73 ± 15.41 | 84.55 ± 15.71 | 81.36 ± 11.93 | 84.82 ± 12.96 |              | 0.2965  |
| Potassium (mg/dL)              | 141.45 ± 2.21 | 140.91 ± 1.64 | 140.18 ± 1.54 | 139.64 ± 2.06 |              | 0.6043  |
| Chloride (mg/dL)               | 4.35 ± 0.35  | 4.27 ± 0.35  | 4.13 ± 0.23  | 4.26 ± 0.24  |              | 0.4547  |
| Carbon Dioxide (mL/min)        | 103.55 ± 2.34 | 102 ± 1.95   | 102.91 ± 1.81 | 102.91 ± 2.26 |              | 0.9183  |
| Calcium (mg/dL)                | 27.55 ± 2.25  | 29.36 ± 1.57  | 28.91 ± 1.58  | 29.36 ± 2.42  |              | 0.1070  |
| Glucose (mg/dL)                | 9.23 ± 0.31  | 8.97 ± 0.35  | 9.21 ± 0.35  | 9.19 ± 0.28  |              | 0.1681  |
| Hemoglobin A1c                 | 5.25 ± 0.27  | 5.10 ± 0.30  | 5.20 ± 0.31  | 5.38 ± 0.26  |              | 0.3925  |

Data reported in mean and standard deviation. P-value is from group by time interaction effect. (ALB:GLOB = Albumin:Globulin Ratio, AST = aspartate aminotransferase, ALT = alanine transaminase, BUN = blood urea nitrogen, eGFR = estimated glomerular filtration rate.)

### 3.4. Blood Pressure and Heart Rate

There was no significant between or within group differences in resting blood pressure or heart rate (p > 0.05, Table 5). Mean and standard deviation are displayed in Table 5.
Table 5. Blood Pressure and Cardiovascular Results.

|                    | PRE       | 30 DAY    | 60 DAY    | 90 DAYS    | p Value  |
|--------------------|-----------|-----------|-----------|------------|----------|
| **Systolic BP (mmHg)** |           |           |           |            |          |
| BHB                | 113.00±10.25 | 112.18±9.66 | 109.00±11.25 | 109.09±9.27 | 0.6480   |
| PLA                | 115.91±11.38 | 117.45±10.35 | 116.64±10.60 | 115.00±8.56 |          |
| **Diastolic BP (mmHg)** |           |           |           |            |          |
| BHB                | 68.27±10.68 | 64.36±7.12 | 63.55±10.00 | 65.45±7.61 | 0.5610   |
| PLA                | 70.82±10.25 | 68.55±11.85 | 70.55±11.10 | 68.36±8.54 |          |
| **Heart Rate (bpm)** |           |           |           |            |          |
| BHB                | 62.55±10.68 | 64.55±7.03 | 65.00±10.00 | 63.82±8.15 | 0.4459   |
| PLA                | 61.64±8.32  | 64.73±8.68 | 61.64±8.41 | 60.91±8.60 |          |

Data reported in mean and standard deviation. P-value is from group by time interaction effect. (BP = blood pressure).

3.5. Profile of Mood States (POMS) & Immune Status Questionnaire (ISQ)

There was no significant between or within group differences for responses to the POMS questionnaire or the ISQ (p > 0.05, Table 6). Mean and standard deviation are displayed in Table 6.

Table 6. Survey Results

|                    | PRE       | 30 DAYS   | 60 DAYS   | 90 DAYS    | p Value  |
|--------------------|-----------|-----------|-----------|------------|----------|
| **Total POMS Score (a.u.)** |           |           |           |            |          |
| BHB                | 82.55±17.06 | 77.36±13.43 | 79.55±12.13 | 86.09±9.97 | 0.7240   |
| PLA                | 73.64±9.14  | 73.91±11.22 | 74.45±10.82 | 78.09±7.83 |          |
| **ISQ Total Score (a.u.)** |           |           |           |            |          |
| BHB                | 9.00±1.10  | 8.73±1.74  | 9.00±1.48  | 8.73±1.42  | 0.2195   |
| PLA                | 9.27±0.47  | 9.45±0.52  | 9.36±0.67  | 9.64±0.50  |          |

Data reported in mean and standard deviation. P-value is from group by time interaction effect.

3.6. Body Composition & Bone Densitometry

There was no significant between or within group differences in any body composition or bone densitometry values (p > 0.05, Table 7). Mean and standard deviation are displayed in Table 7.

Table 7. Body Composition & Bone Densitometry Results.

|                    | PRE       | DAY 90    | p Value  |
|--------------------|-----------|-----------|----------|
| **Total Mass (kg)** |           |           |          |
| BHB                | 72.66±14.24 | 72.80±14.44 | 0.9727   |
| PLA                | 79.53±17.98 | 79.60±18.92 |          |
| **Fat Mass (kg)**  |           |           |          |
| BHB                | 23.21±9.55  | 23.96±10.48 | 0.8739   |
| PLA                | 23.74±6.87  | 25.31±8.26  |          |
| **Fat Free Mass (kg)** |           |           |          |
| BHB                | 49.45±10.96 | 48.84±9.69  | 0.5330   |
| PLA                | 55.79±14.28 | 54.28±12.66 |          |
| **Body Fat %**     |           |           |          |
| BHB                | 31.66±9.44  | 32.29±9.63  | 0.3223   |
| PLA                | 29.96±5.94  | 31.45±5.90  |          |
| **Bone Mineral Density (g/cm²)** | | |          |
| BHB                | 1.13±0.11 | 1.11±0.09 | 0.1530 |
| PLA                | 1.16±0.13 | 1.18±0.11 |          |
| **Bone Mineral Content (g)** | | |          |
| BHB                | 2291.19±369.46 | 2248.45±245.24 | 0.2638 |
| PLA                | 2510.98±501.73 | 2534.13±409.74 |          |

Data reported in mean and standard deviation. P-value is from group by time interaction effect.

4. Discussion

In this study, we demonstrated the safety of exogenous BHB under uncontrolled conditions of daily living. The most significant finding of this study was that sustained 25.5 grams of daily exogenous ketone salt consumption for 90 days was safe for healthy adults and that it had no adverse effect on any blood health markers, hemoglobin A1c, psychological well-being, or cardiovascular markers of health. Comprehensive metabolic panel, complete blood count, and automated differential cell count remained normal and unaltered after supplementing twice daily with exogenous
BHB for 90 days. Furthermore, there were no significant changes in the POMS or ISQ, resting blood pressure, or resting heart rate. The findings in this study support, and further build upon, a previous study by Holland et al. [24] demonstrating that 6 weeks of exogenous ketone salts supplementation did not negatively impact various markers of human health and safety in adults.

There are many controversial views regarding the ketogenic diet, ketosis, and exogenous ketones. Two such views are that ketosis can increase the risk of complications in the liver [27], and the kidneys [28]. However, in human studies, it was demonstrated that the ketogenic diet may improve clinical outcomes of nonalcoholic fatty liver disease [29, 31]. In the present study, we found that markers of liver health; total protein, albumin, globulin, ALB:GLOB ratio, bilirubin, alkaline phosphate, AST, and ALT; were unaffected and no different from placebo with exogenous ketone supplementation in a healthy population over 90 days.

Depending on macronutrient distribution of caloric intake, the ketogenic diet can be considered a high protein diet (≥ 20% of caloric intake). It has been posited that diets higher in protein could lower pH and increase the acidic load on the kidneys [28]. However, the previously referenced study used a high-protein, low-carbohydrate diet, while a typical ketogenic diet consists of low to moderate protein and very-low carbohydrate [30]. With a typical ketogenic diet, Kossof et al. [32] demonstrated no increased risk of kidney stones in children. Our study demonstrated no changes in kidney function markers such as BUN, creatinine, BUN/creatinine ratio, and eGFR in a healthy population over 90 days. In addition, acid-base balance was maintained as demonstrated by blood carbon dioxide and chloride levels.

The ketogenic diet has shown to lead to calcium loss, and in some cases, can increase the risk of bone loss. Previous research has suggested that the ketogenic diet can increase calcium excretion, which can lead to bone mass loss in children and adolescents [33–35]. Our study demonstrated no blood calcium or electrolyte loss, as all electrolyte levels were unchanged over 90 days in a healthy adult population. Moreover, we found no changes in bone mineral density or bone mineral content as assessed by whole-body DXA scans at PRE and Day 90. These results suggest that BHB does not lead to bone density or bone mineral content loss.

Lastly, it has been postulated that electrolytes may alter different markers of cardiovascular health such as blood pressure and heart rate [36]. Exogenous ketone salts, like the ones used in the present study, are bound to calcium and magnesium in order to improve transport and absorption across the gut-blood barrier. Therefore, it is reasonable to investigate if altering dietary intake of electrolytes with the consumption of exogenous ketone salts may have an effect on blood pressure. However, in our present study, systolic blood pressure, diastolic blood pressure, and heart rate were unaffected in the resting state. In addition, blood concentrations of sodium, potassium, chloride, and calcium all remained unaltered.

A limitation of the present study is the method of supplementation, and the lack of exercise and dietary control. Subjects were provided the supplement every 30 days when they came into the laboratory for testing. They were asked to return any unused supplements to the laboratory to help keep subjects honest and to track adherence. Lastly, diet and exercise were not controlled. However, to keep subjects accountable, they were encouraged to track and report dietary intake via a mobile application. Dietary records demonstrated no differences in daily average of total calories consumed (BHB: 1430.71 ± 370.84 vs PLA: 1560.04 ± 394.54 kcal/day, p=0.4381). Future research may seek to directly compare the effects of exogenous ketone esters and exogenous ketone salts.

5. Conclusion

Exogenous ketone salt supplementation (BHB) can be considered safe and well tolerated. BHB showed no changes in comprehensive metabolic panel, automated differential cell count, complete blood count, hemoglobin A1c, resting blood pressure and heart rate or psychological surveys over 90 days of supplementation in a healthy population when compared to PLA. This study established the safety of long term BHB supplementation, but further investigation is needed to examine the efficacy of exogenous ketone supplementation in other areas of health, longevity, cognitive function, and other chronic conditions.

Funding

Pruvit Ventures Inc. (Melissa, Texas USA) financially supported the study and supplied the treatment and control conditions used in this investigation.

Disclosures

Jacob Wilson and Ryan Lowery receive honoraria from Pruvit Ventures Inc. All other authors report no disclosures.

References

[1] Paoli A, Rubini A, Volek JS, et al. Beyond weight loss: a review of the therapeutic uses of very-low-carbohydrate (ketogenic) diets. Eur J Clin Nutr 2013; 67: 789–796.

[2] Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2004; 70: 309–319.

[3] Ballard KD, Quann EE, Kupchak BR, et al. Dietary carbohydrate restriction improves insulin sensitivity, blood pressure, microvascular function, and cellular adhesion markers in individuals taking statins. Nutr Res 2013; 33: 905–912.

[4] Hyatt HW, Kephart WC, Holland AM, et al. A Ketogenic Diet in Rodents Elicits Improved Mitochondrial Adaptations in Response to Resistance Exercise Training Compared to an Isocaloric Western Diet. Front Physiol 2016; 7 Im Internet: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099251/.
Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for diabetes. The New England Journal of Medicine 2004; 350: 290–296.

Sumithran P, Prendergast LA, Delbridge E, et al. Ketosis and appetite-mediating nutrients and hormones after weight loss. European Journal of Clinical Nutrition 2013; 67: 759–764.

Rosen JC, Gross J, Loew D, et al. Mood and appetite during minimal-carbohydrate and carbohydrate-supplemented hypocaloric diets. The American Journal of Clinical Nutrition 1985; 42: 371–379.

Poff, A., Koutnik, A., Deblasi, J., Rogers, C., Kesl, S., Ward, N. and D’Agostino, D. (2018), Characterizing the physiologic effects of exogenous ketone supplements – an alternative or adjuvant to the ketogenic diet. The FASEB Journal, 32: 812.38-812.38. https://doi.org/10.1096/fasebj.2018.32.1_supplement.812.38.

Krotkiewski M. Value of VLCD supplementation with medium chain triglycerides. International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity 2001; 25: 1393–1400.

Neal EG, Chaffe H, Schwartz RH, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. The Lancet Nutrition 2008; 7: 500–506.

Vanattilie TB, Nonas C, Di Rocco A, et al. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 2005; 64: 728–730.

Poff A, Koutnik AP, Egan KM, et al. Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma. Seminars in Cancer Biology 2019; 56: 135–148.

Feinman RD, Pogozielski WK, Astrup A, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition (Burbank, Los Angeles County, Calif) 2015; 31: 1–13.

Yancy WS, Vernon MC, Westman EC. A pilot trial of a low-carbohydrate, ketogenic diet in patients with type 2 diabetes. Metabolic Syndrome and Related Disorders 2003; 1: 239–243.

Cox PJ, Kirk T, Ashmore T, et al. Nutritional Ketosis Alters Fuel Preference and Thereby Endurance Performance in Athletes. Cell Metabolism 2016; 24: 256–268.

Cox PJ, Clarke K. Acute nutritional ketosis: implications for exercise performance and metabolism. Extrem Physiol Med 2014; 3: 17.

Safety and tolerability of the ketogenic diet used for the treatment of refractory childhood epilepsy: a systematic review of published prospective studies - PubMed. Im Internet: https://pubmed.ncbi.nlm.nih.gov/28702868/.

Kwiterovich PO, Vining EPG, Pyzik P, et al. Effect of a high-fat ketogenic diet on plasma levels of lipids, lipoproteins, and apolipoproteins in children. JAMA 2003; 290: 912–920.

Poff A, Koutnik A, Egan B. Nutritional Ketosis with Ketogenic Diets or Exogenous Ketones: Features, Convergence, and Divergence. Current Sports Medicine Reports 2020; 19; 7: 251-259.

Blood and cardiovascular health parameters after supplementing with ketone salts for six weeks | Holland | Journal of Insulin Resistance. Im Internet: https://insulinresistance.org/index.php/jir/article/view/47/172.

McGettigan B, McMahan R, Orlucky D, et al. Dietary Lipids Differentially Shape Nonalcoholic Steatohepatitis Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages. Hepatology 2019; 70: 67–83.

Reddy ST, Wang C-Y, Sakhaee K, et al. Effect of low-carbohydrate high-protein diets on acid-base balance, stone-forming propensity, and calcium metabolism. American Journal of Kidney Diseases 2002; 40: 265–274.

Luukkonen PK, Dufour S, Lyu K, et al. Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease. Proc Natl Acad Sci U S A 2020; 117: 7347–7354.

Franco Cavaleri, Emran Bashar, "Potential Synergies of β-Hydroxybutyrate and Butyrate on the Modulation of Metabolism, Inflammation, Cognition, and General Health", Journal of Nutrition and Metabolism, vol. 2018, Article ID 7195760, 13 pages, 2018. http://sci-hub.tw/10.1155/2018/7195760.

Tendler D, Lin S, Yancy WS, et al. The Effect of a Low-Carbohydrate, Ketogenic Diet on Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci 2007; 52: 589–593.

Kossoff EH, Pyzik PL, Furth SL, et al. Kidney Stones, Carbonic Anhydrase Inhibitors, and the Ketogenic Diet. Epilepsia 2002; 43: 1168–1171.

Hahn TJ, Halstead LR, DeVivo DC. Disordered mineral metabolism produced by ketogenic diet therapy. Calcif Tissue Int 1979; 28: 17–22.

Progressive bone mineral content loss in children with intractable epilepsy treated with the ketogenic diet | The American Journal of Clinical Nutrition | Oxford Academic. Im Internet: https://academic.oup.com/ajcn/article/88/6/1678/4754456.
[35] Willi SM, Oexmann MJ, Wright NM, et al. The Effects of a High-protein, Low-fat, Ketogenic Diet on Adolescents With Morbid Obesity: Body Composition, Blood Chemistries, and Sleep Abnormalities. Pediatrics 1998; 101: 61–67.

[36] Iqbal S, Klammer N, Ekmekcioğlu C. The Effect of Electrolytes on Blood Pressure: A Brief Summary of Meta-Analyses. Nutrients 2019; 11 Im Internet: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627949/.